February 12, 2021 11:21 AM EST
Peer Review

Ex-Vi­vid­ion chief Diego Mi­ralles finds 'dream team' at stealthy Flag­ship port­fo­lio com­pa­ny; Astel­las looks in­ward to se­lect CBO and CSO

Alex Hoffman

Copy Chief

Kathy Wong

Editor

Nicole DeFeudis

Editor

Al­most three months af­ter leav­ing Vi­vid­ion Ther­a­peu­tics, where he re­cent­ly signed a $135 mil­lion Roche deal, Diego Mi­ralles has land­ed the top spot on …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

Will CRISPR mat­ter?

Te­va launch­es Ste­lara biosim­i­lar at 85% dis­count as wider field emerges

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times